Cardiol Therapeutics Inc
Commented by Nico Popp on November 9th, 2026 | 23:05 CET
Billion-dollar opportunity in cardiac therapy: Cardiol Therapeutics, Kiniksa and Novo Nordisk
Created and Published on Behalf of Cardiol Therapeutics
The treatment of inflammatory heart diseases is becoming one of the most lucrative segments of the pharmaceutical industry. The only drug approved to date for recurrent pericarditis is expected to exceed USD 1 billion in revenue this year. While established industry heavyweights generate enormous revenues from injectable biologics, emerging biotechnology companies are preparing the next stage of development. The focus is on the search for oral therapies intended to open up access to treatment for a much broader patient population.
Read
Commented by Matthias Schomber on October 30th, 2026 | 05:27 CET
BioNTech seeks a breakthrough with its cancer pipeline, DroneShield battles short sellers and Cardiol Therapeutics targets a rebound!
Created and published on behalf of Cardiol Therapeutics
Biotech heavyweights such as BioNTech and defence and drone stocks such as DroneShield are currently looking for unambiguous and clear trend signals. While BioNTech is grappling with clinical setbacks and internal discussions despite strategic collaborations, defence specialist DroneShield is weighed down by persistent short-selling pressure and rather subdued growth expectations. At the same time, Cardiol Therapeutics is coming into focus as a technically promising candidate that, following a correction lasting several months, could now find the long-awaited bottom at a prominent technical support zone. This equity analysis of the 3 stocks examines the financial data, operational milestones and strategic opportunities as well as the risks of the three companies to provide guidance that is as well-founded as possible. Read on to find out where attractive opportunities are now emerging.
Read
Commented by Stefan Feulner on October 20th, 2026 | 05:23 CEST
AstraZeneca, Cardiol Therapeutics, Kiniksa – New hope for heart patients
Cardiovascular diseases remain among the greatest medical challenges worldwide. While established pharmaceutical groups invest billions in new active ingredients and artificial intelligence, specialised biotech companies are developing targeted therapies for conditions that have so far been difficult to treat, such as recurrent pericarditis. Patients often suffer from painful relapses and require long-term treatment. New medicines could fundamentally change how these conditions are managed. For investors, this brings into focus companies that already market approved products or are awaiting pivotal clinical trial results.
Read
Commented by Fabian Lorenz on October 12th, 2026 | 05:30 CEST
After 600% Gains with Moderna! Cardiol Therapeutics Poised for a Revaluation - Analysts See Significant Upside Potential
With gains of more than 600%, Moderna is the Nasdaq’s best-performing stock so far this year. Much of its future growth potential may already be priced in, prompting Citigroup to recommend selling shares in the mRNA specialist. Analysts, however, see significant upside potential in another biotech company: Cardiol Therapeutics. The Canadian biotechnology company focuses on inflammatory heart diseases, and its lead drug candidate, CardiolRx™, is already in Phase 3 clinical trials. Following strong Phase 2 data, the stock more than doubled between July and September. After a subsequent pullback, could this present an attractive entry opportunity? In a recent interview, the CEO explains why he remains optimistic. Two research firms recommend buying the stock and see the potential for a multiple-fold increase in its share price.
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read
Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST
BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?
On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.
Read
Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST
BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave
The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.
Read
Commented by Armin Schulz on July 9th, 2024 | 07:07 CEST
Varta, Cardiol Therapeutics, Evotec - ATTENTION: Something is happening here!
The stock markets are currently seeing increased activity in Varta, Cardiol Therapeutics, and Evotec. Investors should take advantage of the resulting opportunities. Increased volatility and trading volumes can offer attractive short-term gains, while improved liquidity facilitates entry and exit. Additional information flows and momentum effects enhance the dynamics of these stocks, although they also carry increased risks. Sound analysis and prudent risk management are, therefore, essential. We take a closer look at what is currently happening with these three stocks.
Read